Calculus Capital invests GBP2.5m in Axol Bioscience
Private equity firm Calculus Capital, a leading EIS and VCT investor, has completed its third deal in two weeks, investing GBP2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells. Axol supplies high quality human cells – especially live human neurons
